He has typically allied with Big Pharma, pointing fingers at pharmacy benefit managers. But a bipartisan agreement could do away with that gambit.
PBMs
Posted inPolitics
Crypto-Backed California Republican Attacks Opponent for Owning Crypto
It’s part of a Vietnamese-language red-baiting campaign by Rep. Michelle Steel, who faces a stiff challenge in California’s 45th Congressional District against veteran and pharmacy owner Derek Tran.
Posted inVideos
The Prospect Weekly Roundup: Every News Story That’s Happened This Week
David Dayen and Maureen Tkacik try their best to get through all of them.
Posted inHealth and Social Policy
FTC Sues PBMs for Jacking Up Insulin Prices
The case against Caremark, Express Scripts, and Optum Rx is the first against this element of the pharmaceutical transaction chain.
Posted inEconomic Policy
Small-Business Regulators Highlight Protection From Predation
Contrary to the discussion at the presidential level, small businesses are seeking access to credit and a level playing field for their enterprises.
Posted inHealth and Social Policy
The Bipartisan Reform Opportunity Staring Kamala Harris in the Face
Both parties want to crack down on pharmacy benefit managers. The vice president could help get it done.
Posted inTAP
FTC Comes for PBMs
Today on TAP: An interim report shows how pharmaceutical middlemen raise drug prices and damage care.
Posted inHealth and Social Policy
New Bill Seeks to End Drug Shortages
The Senate Finance Committee wants to create a new program to incentivize better practices. Critics say there’s an easier way: end kickbacks between suppliers and bulk purchasers.
Posted inHealth and Social Policy
Our Uniquely American Drug Shortages
More drugs are in short supply than ever before. We’ve known the reason why for a long time: monopolistic middlemen.
Posted inHealth and Social Policy
The PBM-Insurer Mafia Comes for Community Pharmacies
UnitedHealth, CVS, and Cigna’s PBMs are using their market share and pull in Washington to drive one of the key levers to manage health care costs—independent pharmacies—out of business.
